| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Travere Therapeutics, Inc. (TVTX) has 16 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. TVTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 440.1K | $19.64M | -64,000 | |
| Other | 138.6K | $6.19M | -7,215 | |
| Other | 123.1K | $5.49M | - | |
| CFO | 116.9K | $5.22M | -8,262 | |
| Other | 111.5K | $4.98M | -8,233 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Heerma Peter53 | Chief Commercial Officer | Sell | 7,310 | $32.12 | $234,797.20 | -5.3% | +34.3% | - | |
| Feb 3, 2026 | Rote William E.58 | Chief Research Officer | Sell | 12,446 | $32.87 | $409,100.02 | -10.2% | +34.3% | - | |
| Jan 6, 2026 | Inrig Jula45 | Chief Medical Officer | Sell | 2,476 | $39.74 | $98,404.33 | -1.4% | -11.1% | - | |
| Dec 24, 2025 | Rote William E.58 | Chief Research Officer | Sale+OE | 60,000 | $40.10 | $2,406,180.00 | -37.2% | -33.5% | - | |
| Dec 24, 2025 | Inrig Jula45 | Chief Medical Officer | Sale+OE | 15,000 | $42.00 | $630,004.50 | -14.5% | -33.5% | - | |
| Dec 24, 2025 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sell | 7,402 | $40.00 | $296,080.00 | -16.2% | -33.5% | - | |
| Dec 24, 2025 | Heerma Peter53 | Chief Commercial Officer | Sell | 4,980 | $40.00 | $199,200.00 | -4.2% | -33.5% | - | |
| Dec 15, 2025 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sell | 2,910 | $36.00 | $104,760.00 | -6.0% | -19.4% | - | |
| Dec 1, 2025 | Cline Christopher R.50 | Chief Financial Officer | Sale+OE | 20,000 | $35.01 | $700,202.00 | -17.8% | -16.1% | - | |
| Nov 4, 2025 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sale+OE | 67,115 | $36.00 | $2,416,140.00 | -58.0% | -3.0% | - |